KR101342110B1 - Process for Preparing Edible Oil Containing Ajoene from Garlic - Google Patents
Process for Preparing Edible Oil Containing Ajoene from Garlic Download PDFInfo
- Publication number
- KR101342110B1 KR101342110B1 KR1020120044932A KR20120044932A KR101342110B1 KR 101342110 B1 KR101342110 B1 KR 101342110B1 KR 1020120044932 A KR1020120044932 A KR 1020120044932A KR 20120044932 A KR20120044932 A KR 20120044932A KR 101342110 B1 KR101342110 B1 KR 101342110B1
- Authority
- KR
- South Korea
- Prior art keywords
- garlic
- azoene
- milk fat
- allicin
- oil
- Prior art date
Links
- 240000002234 Allium sativum Species 0.000 title claims abstract description 123
- 235000004611 garlic Nutrition 0.000 title claims abstract description 122
- 238000004519 manufacturing process Methods 0.000 title claims description 28
- 239000008157 edible vegetable oil Substances 0.000 title description 12
- IXELFRRANAOWSF-UHFFFAOYSA-N cis-ajoene Natural products C=CCSSC=CCS(=O)CC=C IXELFRRANAOWSF-UHFFFAOYSA-N 0.000 title description 5
- IXELFRRANAOWSF-FNORWQNLSA-N (E)-Ajoene Chemical compound C=CCSS\C=C\CS(=O)CC=C IXELFRRANAOWSF-FNORWQNLSA-N 0.000 title description 4
- IXELFRRANAOWSF-CYBMUJFWSA-N ajoene Natural products C=CCSSC=CC[S@](=O)CC=C IXELFRRANAOWSF-CYBMUJFWSA-N 0.000 title description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 53
- 235000021243 milk fat Nutrition 0.000 claims abstract description 53
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 34
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000010081 allicin Nutrition 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 239000006000 Garlic extract Substances 0.000 claims abstract description 12
- 235000020706 garlic extract Nutrition 0.000 claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 26
- 239000010647 garlic oil Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000014121 butter Nutrition 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241000282994 Cervidae Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- 239000003925 fat Substances 0.000 description 25
- 235000019197 fats Nutrition 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000035484 reaction time Effects 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000014593 oils and fats Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008169 grapeseed oil Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- 241000501754 Astronotus ocellatus Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940029982 garlic powder Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007886 soft shell capsule Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000005211 surface analysis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- IXELFRRANAOWSF-ALCCZGGFSA-N (Z)-Ajoene Chemical compound C=CCSS\C=C/CS(=O)CC=C IXELFRRANAOWSF-ALCCZGGFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 150000008115 S-alk(en)yl-l-cysteine sulfoxides Chemical class 0.000 description 1
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010993 response surface methodology Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 150000008122 vinyldithiins Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/105—Natural spices, flavouring agents or condiments; Extracts thereof obtained from liliaceae, e.g. onions, garlic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/212—Garlic
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Dairy Products (AREA)
Abstract
본 발명은 마늘 분쇄물, 마늘 착즙액, 마늘 건조 분말 및 마늘 추출물 중에서 선택되는 어느 하나 이상의 알리신(allicin) 함유 마늘 재료를 준비하는 단계; 상기 알리신 함유 마늘 재료를 유지방과 혼합하는 단계; 및 상기 알리신 함유 마늘 재료와 유지방의 혼합물을 가열하여 반응시키는 단계;를 포함하는 유지방을 이용한 아조엔 함유 마늘 오일의 제조방법에 관한 것으로, 본 발명의 방법을 통해 종래 식물성 유지를 사용하는 방법에 비해 2 배 이상 높은 함량으로 아조엔을 생성시킬 수 있다.The present invention comprises the steps of preparing any one or more allicin (allicin) containing garlic material selected from garlic ground, garlic juice, garlic dry powder and garlic extract; Mixing the allicin-containing garlic material with milk fat; And a step of heating the mixture of the allicin-containing garlic material and the milk fat and reacting the same. It is possible to produce azoene at a content of more than two times higher.
Description
본 발명은 동물성 지질, 특히 유지방(milk fat)을 이용하여 마늘로부터 아조엔이 함유된 마늘 오일 제품을 제조하는 방법에 관한 것이고, 이를 유효성분으로 하는 건강기능식품에 관한 것이다.
The present invention relates to a method for producing garlic oil products containing azoene from garlic using animal lipids, in particular milk fat, and to a health functional food using the same as an active ingredient.
마늘(Allium sativum L.)은 백합과(Lilliaceae) 파속에(Allium) 속하는 구근작물로서 최근 많은 연구자들의 연구결과에서 암 예방효과, 혈액순환 장애 예방 효과 및 항산화 작용과 같은 다양한 약리적 생리활성이 있는 것으로 보고되고 있다. 이러한 마늘의 약리적 생리활성을 나타내는 주요성분은 에스-알켄닐-엘-시스테인 설옥사이드류(S-alk(en)yl-L-cysteine sulfoxides)의 하나인 일명 알린(alliin)으로 불리는 에스-알릴-엘-시스테인 설옥사이드(S-allyl-L-cysteine sulfoxide)가 마늘 중의 효소인 알린나아제(allinase)의 작용을 받아 생성된 알리신(allicin)과 알리신의 중합 및 분해작용에 의하여 생성된 아조엔(ajoene) 및 비닐 다이신(vinyl dithiins)등 각종 황 화합물들인 것으로 알려져 있다(Lawson et al. Planta . Med . 57:363-370(1991)). 아조엔(E,Z-4,5,9-trithiadodeca-1,6,11-triene-9-oxide)은 순수 알리신으로 부터 생성되는데 알리신 보다 더 큰 화학적 안정성을 갖고 있다는 장점이 있다. 아조엔은 두 가지 이성질체를 가지며, 하기 화학식 1은 Z-아조엔(cis form), 화학식 2는 E-아조엔(trans form)이다.Garlic ( Allium sativum L.) is a bulbous crop belonging to the genus Liliumaceae ( Allium ), and many researchers have recently reported that it has various pharmacological physiological activities such as cancer prevention, blood circulation disorder prevention and antioxidant activity. . The main component that shows the pharmacological physiological activity of garlic is S-alyl, also known as allin, which is one of S-alk (en) yl-L-cysteine sulfoxides. S-allyl-L-cysteine sulfoxide is produced by the polymerization and decomposition of allicin and allicin produced by the action of the enzyme alinase, which is an enzyme in garlic. and various sulfur compounds such as ajoene) and vinyl dithiins (Lawson et al. Planta . Med . 57: 363-370 (1991)). Azoene (E, Z-4,5,9-trithiadodeca-1,6,11-triene-9-oxide) is produced from pure allicin and has the advantage of greater chemical stability than allicin. Azoene has two isomers, in which Chemical Formula 1 is Z-Azoene ( cis form), and Chemical Formula 2 is E-Azoene ( tran s form).
화학식 1
화학식 2(2)
아조엔은 마늘을 분쇄하여 유기용매 또는 식용유와 함께 반응시키면 생성되는데, 이는 Block et al.에 의하여 최초로 보고되었다(J. Am . Chem . Soc . 106: 8295-8296(1984)). Block의 연구결과에 의하면 아조엔은 혈소판의 응고에 관련되는 모든 인자를 억제하는 효과가 있으며 이의 효력은 아스피린의 혈소판 응집억제효과와 같은 효력이 있다고 하였다(Sci . Am . 252:94-99(1985)).Azoene is produced by grinding garlic and reacting it with an organic solvent or cooking oil, which was first reported by Block et al. ( J. Am . Chem . Soc . 106: 8295-8296 (1984)). According to Block's study, azoene has the effect of inhibiting all factors related to platelet coagulation and its effect is the same as that of aspirin inhibiting platelet aggregation ( Sci . Am . 252: 94-99 (1985). )).
아조엔의 생물학적 활성은 혈전증을 막고, 항균작용을 포함하며(Stenier M. et al. J. Nutr. 131:980S-984S(2001)), 3-하이드록시-3-메틸-글루타릴-CoA(HMG-CoA) 환원효소 억제를 통하여 콜레스테롤 생합성을 감소시킨다(Rolf et al. Biochimica et Biophysica Acta 1213:57-62(1994)). 마늘이 체내 지질대사에 영향을 미쳐 혈중 지질량의 감소 효과뿐만 아니라 고혈압, 심장병, 뇌졸중 등의 직접적 원인인 동맥경화증, 혈전증, 혈관수축에 의한 혈행 장해의 억제 효과가 있음을 보고하였다.The biological activity of azoene prevents thrombosis, includes antimicrobial activity (Stenier M. et al. J. Nutr . 131: 980S-984S (2001)), 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reduces cholesterol biosynthesis through inhibition of reductase (Rolf et al. Biochimica et Biophysica Acta 1213: 57-62 (1994). Garlic affects lipid metabolism in the body and has been reported to reduce blood lipid levels as well as inhibit blood circulation disorders caused by atherosclerosis, thrombosis, and vascular contraction, which are direct causes of hypertension, heart disease, and stroke.
Apitz-Castro et al.(Biochim . Biophys . Acta . 1094:269-280 (1991))가 보고한 아조엔의 혈소판 응고 억제의 기작 규명을 통해 폐전증, 동맥경화증, 고지혈증 등의 순환계질병의 치료제로서 가능성을 보였다. 또한 아조엔이 발암물질인 아플라톡신 B와 DNA의 작용을 억제하는 기능(Tadi et al. Cancer Letters 59:89-94(1991)) 및 종양세포에 대한 세포독성능도 연구되었다(Scharfenberg et al. Cancer Letters 53:103-108(1990)). Apitz-Castro et al. ( Biochim . Biophys . Acta . 1094: 269-280 (1991)) reported the mechanism of inhibition of platelet coagulation of azoene as a therapeutic agent for circulatory diseases such as pulmonary disease, atherosclerosis and hyperlipidemia. Showed the possibility. Azoene also inhibits the action of carcinogen Aflatoxin B and DNA (Tadi et al. Cancer Letters 59: 89-94 (1991)) and cytotoxic activity against tumor cells (Scharfenberg et al. Cancer Letters 53: 103-108 (1990)).
또한 아조엔의 항진균/항균 작용(Yoshida et al. Appl . Environ . Microbiol . 53:615-617 (1987)), 항바이러스효과(Werber et al. Planta Med . 58:417-423 (1992)) 등이 보고되어 있으며 에이즈에도 효과가 있는 것으로 보고되어있다(Tatarintsev et al. Int . Conf . AIDS 8:19-24). 아조엔은 항박테리아/항균제재인 5-플루오르사이토신과 비슷한 정도의 효과를 나타낸다. In addition, antifungal / antifungal action of azoene (Yoshida et al. Appl . Environ . Microbiol . 53: 615-617 (1987)), antiviral effect (Werber et al. Planta Med . 58: 417-423 (1992)), and have been reported to be effective against AIDS (Tatarintsev et al. Int . Conf . AIDS 8: 19-24). Azoene has an effect similar to that of 5-fluorocytosine, an antibacterial / antibacterial agent.
아조엔은 원료마늘, 마늘다데기 및 건조마늘과 같은 일반 가공제품 중에서는 존재하지 않으며 일반적으로 극성이 낮은 유기용매 또는 유지와 혼합한 경우 생성되는데 이의 생성량은 용매의 극성, 지방산조성 및 반응조건(온도 및 시간)에 따라 많은 차이가 있다. Azoene does not exist in general processed products such as raw garlic, garlic stalk and dried garlic and is generally produced when mixed with low polar organic solvents or fats and oils. And time).
Lawson은 마늘을 식물성 유지에 넣어 얻은 마늘 착즙액에서 아조엔을 60 내지 148 ㎍/g 얻었으며 E-아조엔이 Z-아조엔 보다 항상 많이 생성되며 일반적으로 E형이 Z형보다 2배 이상 높은 것으로 보고하였다. Lawson obtained 60 to 148 ㎍ / g of azoene from garlic juice obtained by adding garlic to vegetable oils, and E- azoene is always produced more than Z-azoene, and E type is generally more than twice as high as Z type. Reported.
일본특허공개 소62-129224호에서 마늘을 에틸알코올, 메틸알코올과 같은 pH 2-6의 유기용매에 혼합하여 40-90℃로 가열하여 아조엔을 추출하는 과정이 개시되다. 이 과정에서 마늘 1 ㎏ 당 약 900 ㎍의 아조엔만이 추출되어 많은 아조엔을 얻기 위해서는 많은 양의 마늘이 필요하다. 이러한 저효율의 아조엔 생성 과정은 식품 및 의약품에 이용되기 부족하다.In Japanese Patent Laid-Open No. 62-129224, a process of extracting azoene by mixing garlic with an organic solvent of pH 2-6 such as ethyl alcohol and methyl alcohol and heating to 40-90 ° C. is disclosed. In this process, only about 900 μg of azoene per kilogram of garlic is extracted, and a large amount of garlic is required to obtain a large amount of azoene. This low efficiency azoene production process is insufficient for use in food and medicine.
일본특허공개 평8-84570호 및 평11-318377호는 마늘에 물을 넣고 분쇄하여, pH를 6 내지 8로 조정한 후 식용유지를 혼합하고 0 내지 50 ℃로 유지함으로써, 마늘 1 ㎏ 당 303 내지 404 mg 또는 유지 1g 당 417 내지 503 ㎍의 아조엔을 얻었으나, 중성중쇄지방유(MCT유), 옥배유, 샐러드유 등의 식물성유지를 사용한 것으로 반응온도가 낮고, Z/E 비율이 4 내지 5 수준에 불과하였다.Japanese Patent Application Laid-Open Nos. 8-84570 and 11-318377 are crushed by adding water to garlic and adjusting the pH to 6 to 8, then mixing the edible oils and maintaining the temperature at 0 to 50 DEG C. 417 mg to 503 g of azoene was obtained per 404 mg or 1 g of fats and oils, but vegetable fats such as neutral medium-chain fatty oil (MCT oil), jade oil, and salad oil were used. It was only.
본 발명은 동물성 지질, 특히 유지방(milk fat)을 이용하여 마늘로부터 아조엔이 함유된 마늘 오일 제품의 제조방법에 관한 것이고, 이를 유효성분으로 하는 건강기능식품에 관한 것이다.
The present invention relates to a method for producing a garlic oil product containing azoene from garlic using animal lipids, in particular milk fat, and to a health functional food using the same as an active ingredient.
본 발명자들은 마늘에 있는 기능성 또는 의약 유효성분인 아조엔의 극대화할 수 있는 제조 방법을 최적화할 수 있는 공정을 개발하고자 노력하였다. 그 결과, 본 발명자들은 동물성 지질, 특히 유지방을 이용한 아조엔 제조 공정을 개발하였고, 종래의 기술들보다 2배 이상의 수율로 아조엔을 제조할 수 있는 공정을 확립함으로써, 본 발명을 완성하게 되었다.The present inventors endeavored to develop a process for optimizing a method for maximizing the production of azoene, which is a functional or medicinal active ingredient in garlic. As a result, the present inventors have developed a process for producing azoene using animal lipids, in particular, milk fat, and have completed the present invention by establishing a process capable of producing azoene at a yield more than twice that of conventional techniques.
따라서, 본 발명의 목적은 아조엔이 함유된 마늘 오일의 제조방법 및 그로부터 제조된 아조엔 함유 마늘 오일을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a method for producing garlic oil containing azoene and azoene-containing garlic oil prepared therefrom.
본 발명의 다른 목적은 상기 아조엔 함유 마늘 오일을 유효성분으로 함유하는 건강기능식품을 제공하는데 있다.Another object of the present invention to provide a health functional food containing the azoene-containing garlic oil as an active ingredient.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.
Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명은 마늘 퓨레, 마늘 착즙액, 건조 마늘 분말 및 마늘 추출물 중에서 선택되는 어느 하나 이상의 알리신(allicin) 함유 마늘 재료를 준비하는 단계; 상기 알리신 함유 마늘 재료를 유지방과 혼합하는 단계; 및 상기 알리신 함유 마늘 재료와 유지방의 혼합물을 가열하는 단계;를 포함하는 유지방을 이용한 아조엔 함유 마늘 오일의 제조방법을 제공한다.The present invention comprises the steps of preparing any one or more allicin (allicin) containing garlic material selected from garlic puree, garlic juice, dried garlic powder and garlic extract; Mixing the allicin-containing garlic material with milk fat; And heating the mixture of allicin-containing garlic material and milk fat.
본 발명에서 "마늘 오일"은 마늘 유래 성분 또는 마늘 유래 성분으로부터 생성된 물질을 함유하는 반제품 또는 완제품 형태의 유지방으로서, 유지방을 교동, 연압하여 제조하는 버터를 제외한 유지방 함유 제품을 의미하며, "마늘 퓨레"는 생마늘을 압착 또는 물리적 파쇄 등의 방법으로 분쇄한 마늘 분쇄물을 의미하고, "마늘 착즙액"은 상기 마늘 분쇄물로부터 얻은 착즙액을 의미하거나, 또는 마늘 착즙액을 여과 또는 원심분리 등으로 고액분리할 때 생성되는 액상부를 의미하며, "마늘 착즙 잔사"는 상기 착즙액을 제조하고 남은 잔사 또는 고상부를 의미하고, "마늘 추출물"은 상기 마늘 퓨레, 마늘 착즙액, 마늘 착즙 잔사 또는 건조 마늘을 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합용매로 추출한 것이다. 탄소수 1 내지 4의 저급 알코올로는 메탄올, 에탄올, 부탄올, 프로판올 등이 있고, 바람직하게는 메탄올 또는 에탄올이며, 더욱 바람직하게는 에탄올이다. 마늘 추출물은 마늘 재료에 포함된 알리신을 최대한 활용하기 위하여, 마늘 재료, 특히 마늘 착즙 잔사를 펙틴 및 셀룰로오스 분해 효소 중에서 선택되는 어느 하나 이상의 효소를 첨가한 물을 마늘 재료와 반응시켜 얻은 마늘 효소분해 추출물을 포함한다.In the present invention, "garlic oil" is a milk product in the form of a semi-finished or finished product containing a garlic-derived component or a substance derived from a garlic-derived component, means a milk-containing product other than butter prepared by moving and pressing milk fat, and "garlic "Pure" means a garlic pulverized by crushing the raw garlic by a method such as pressing or physical crushing, "Garlic juice" means a juice obtained from the garlic crushed, or by filtering or centrifuging the garlic juice Refers to the liquid portion produced when the solid-liquid separation, "garlic juice residue" refers to the residue or solid phase remaining after producing the juice, "garlic extract" is the garlic puree, garlic juice juice, garlic juice residue or dried Garlic is extracted with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. Lower alcohols having 1 to 4 carbon atoms include methanol, ethanol, butanol, propanol, and the like, preferably methanol or ethanol, and more preferably ethanol. Garlic extract is a garlic enzymatic extract obtained by reacting garlic ingredients, especially garlic juice residues, with water containing any one or more enzymes selected from pectin and cellulose degrading enzymes to make the best use of allicin contained in garlic ingredients. It includes.
마늘 퓨레를 직접 유지와 혼합하여 아조엔을 생성할 경우에는 마늘 퓨레의 입자 크기는 20메쉬 이하로 제조하는 것이 바람직하며, 또한 마늘 건조 분말을 식용유지와 혼합하여 아조엔을 생성할 경우에는 분말입자의 크기는 가급적 60 메쉬 이하로 하는 것이 바람직하다.When the garlic puree is mixed with fat or oil directly to produce azoene, the particle size of the garlic puree is preferably manufactured to 20 mesh or less. Also, when the garlic dry powder is mixed with edible oil and fat to produce azoene, the powder particles The size of is preferably 60 mesh or less.
상기 본 발명의 마늘 퓨레, 마늘 착즙액, 건조 마늘 분말 및 마늘 추출물 중에서 선택되는 어느 하나 이상의 알리신(allicin) 함유 마늘 재료로는 바람직하게는 건조 중량 기준으로 2 내지 10 mg/g, 더욱 바람직하게는 4 내지 10 mg/g의 알리신을 포함하고 있다. Garlic puree, garlic juice, dried garlic powder of the present invention and any one or more allicin (allicin) containing garlic material selected from garlic extract is preferably 2 to 10 mg / g, more preferably on a dry weight basis 4-10 mg / g of allicin.
본 발명에서 알리신 함유 마늘 재료와 반응시키는 유지방은 동물의 젖(乳)에서 지방 성분을 농축한 것으로, 지방(fat), 스테롤, 모노글리세리드, 다이글리세리드, 트리글리세리드, 인지질 및 지방산을 포괄적으로 포함하는 생체분자를 의미하고, 100 % 순수한 유지방일 필요는 없으며, 30 내지 99 중량%, 더욱 바람직하게는 32 내지 90 중량% 지방을 함유하는 것이며, 더더욱 바람직하게는 80 내지 90 중량%이다. 본 발명에서 사용되는 유지방은 생크림 또는 버터일 수 있고, 바람직하게는 버터이며, 소, 염소, 양, 말, 낙타, 당나귀, 사슴, 물소 또는 야크의 밀크로부터 유래된 것일 수 있다.In the present invention, the milk fat which is reacted with the allicin-containing garlic material is a concentrated fat component in the milk of an animal, and is a living body including fat, sterol, monoglyceride, diglyceride, triglyceride, phospholipid and fatty acid comprehensively. It means a molecule and does not need to be 100% pure milk fat, but contains 30 to 99% by weight, more preferably 32 to 90% by weight fat, even more preferably 80 to 90% by weight. The milk fat used in the present invention may be fresh cream or butter, preferably butter, and may be derived from milk of cow, goat, sheep, horse, camel, donkey, deer, buffalo or yak.
본 발명에서 이용되는 유지방의 지방산 조성은 다음과 같이 포화 지방산 및 불포화 지방산을 포함한다(참조: National Research Council, 1976, Fat Content and Composition of Animal Products, Printing and Publishing Office, National Academy of Science, ISBN 0-309-02440-4;p. 203): 포화 지방산(라우르산 2-5%, 미리스트산 5-20%, 팔미트산 20-40%, 및 스테아르산 5-20%), 불포화 지방산(올레산 15-30%, 팔미토레산 1-8%, 리놀레산 1-6% 및 리놀렌산 0.5-3%). 보다 바람직하게는 본 발명에서 이용되는 유지방의 지방산 조성은 포화 지방산(라우르산 2.5-4%, 미리스트산 10-15%, 팔미트산 28-35%, 및 스테아르산 8-13%), 불포화 지방산(올레산 20-27%, 팔미토레산 2-6%, 리놀레산 2-5% 및 리놀렌산 0.8-2%)이다.The fatty acid composition of milk fat used in the present invention includes saturated fatty acids and unsaturated fatty acids as follows (National Research Council, 1976, Fat Content and Composition of Animal Products, Printing and Publishing Office, National Academy of Science, ISBN 0). -309-02440-4; p. 203): saturated fatty acids (2-5% lauric acid, 5-20% myristic acid, 20-40% palmitic acid, and 5-20% stearic acid), unsaturated fatty acids (15-30% oleic acid, 1-8% palmitoleic acid, 1-6% linoleic acid and 0.5-3% linolenic acid). More preferably, the fatty acid composition of the milk fat used in the present invention is saturated fatty acid (2.5-4% lauric acid, 10-15% myristic acid, 28-35% palmitic acid, and 8-13% stearic acid), Unsaturated fatty acids (20-27% oleic acid, 2-6% palmitoleic acid, 2-5% linoleic acid and 0.8-2% linolenic acid).
본 발명에서 알리신 함유 마늘 재료와 유지방의 혼합비율은, 알리신 함유 마늘 재료 100 중량부에 대하여, 지방 함량이 80 중량%인 유지방을 기준으로 유지방이 40 내지 400 중량부, 더욱 바람직하게는 70 내지 380 중량부, 더더욱 바람직하게는 60 내지 150 중량부이다. 상기 범위를 벗어나는 경우 원하는 함량으로 아조엔이 강화된 유지를 얻을 수 없고, 60 내지 400 중량부 범위에서 400 ㎍/g 이상의 아조엔 함유 유지를 얻을 수 있으며, 60 내지 150 중량부 범위에서 700 내지 2000 ㎍/g 이상의 아조엔 함유 마늘 오일을 얻을 수 있다.In the present invention, the mixing ratio of the allicin-containing garlic material and the milk fat is 40 to 400 parts by weight, more preferably 70 to 380, based on the milk fat having a fat content of 80% by weight, based on 100 parts by weight of the allicin-containing garlic material. Parts by weight, even more preferably 60 to 150 parts by weight. If it is out of the above range it is not possible to obtain a fat and oil azoen-enhanced fat in the desired content, it is possible to obtain azoene-containing fats of 400 μg / g or more in the 60 to 400 parts by weight, 700 to 2000 in the 60 to 150 parts by weight range Azoene-containing garlic oils of µg / g or more can be obtained.
특히 본 발명에서는 알리신 함유 마늘 재료를 유지방과 혼합하는 단계에 초음파 처리, 균질 및 교반 중에서 하나 이상의 공정을 통해 지방 입자의 크기를 분쇄하는 것이 바람직하다. 지방 입자의 크기가 작게 분쇄되면서 마늘 재료와 유지방의 반응 표면적의 증가로 아조엔의 생성량이 증가한다. In particular, in the present invention, in the step of mixing the allicin-containing garlic material with the milk fat, it is preferable to grind the size of the fat particles through one or more processes of sonication, homogenization and stirring. As the size of fat particles is reduced, the production of azoene increases due to the increase in the reaction surface area of garlic and milk fat.
본 발명에서 상기 알리신 함유 마늘 재료를 유지방과 혼합물을 가열하는 단계는 바람직하게는 40 내지 80 ℃, 더욱 바람직하게는 50 내지 70 ℃, 더더욱 바람직하게는 60 내지 70 ℃에서 수행된다. 상기 하한치 미만에서는 반응시간이 늘어나고, 반응시간을 늘리더라도 비례해서 아조엔의 생성량이 증가하지 않고, 상기 상한치를 초과할 경우 아조엔의 안정성이 저하되어 Z/E 비율이 감소한다. 또한 60 내지 70 ℃ 범위를 벗어나는 경우 유지당 아조엔의 전체 생성량에는 변함이 없으나, Z/E 비율이 현저히 감소하여 6 미만이 되어, Z/E 비율 6 이상, 예를 들어, 8 내지 12, 또는 그 이상을 달성할 수 없다. 이는 생리활성이 높은 Z형 아조엔의 비율이 감소됨을 의미한다.In the present invention, the step of heating the mixture with milk fat containing the allicin-containing garlic material is preferably performed at 40 to 80 ° C, more preferably 50 to 70 ° C, even more preferably 60 to 70 ° C. Below the lower limit, the reaction time increases, and even if the reaction time is increased, the amount of azoene produced does not increase proportionally. When the upper limit is exceeded, the stability of the azoene is lowered and the Z / E ratio decreases. In addition, if the out of the range of 60 to 70 ℃ does not change the total production of azoene per fat or oil, the Z / E ratio is significantly reduced to less than 6, Z / E ratio of 6 or more, for example, 8 to 12, or No more can be achieved. This means that the ratio of Z-type azoene with high physiological activity is reduced.
본 발명에서 상기 알리신 함유 마늘 재료를 유지방과 혼합물을 가열하는 단계는 바람직하게는 1 내지 6시간, 더욱 바람직하게는 1.5 내지 4시간, 더더욱 바람직하게는 2 내지 3시간이다.In the present invention, the step of heating the mixture with milk fat containing the allicin-containing garlic material is preferably 1 to 6 hours, more preferably 1.5 to 4 hours, even more preferably 2 to 3 hours.
상기 방법을 통해 제조된 아조엔 강화 유지는 E-아조엔에 대한 Z-아조엔의 비율이 8 이상이며, 아조엔 함량이 600 ㎍/g 이상이고, 더욱 바람직하게는 E-아조엔에 대한 Z-아조엔의 비율이 10 내지 12이며, 아조엔 함량이 1000 내지 2000 ㎍/g 이다.The azoene fortified fat prepared by the above method has a ratio of Z-azoene to E-azoene of 8 or more, an azoene content of 600 µg / g or more, and more preferably Z to E-azoene. -The ratio of azoene is 10-12, and the azoene content is 1000-2000 µg / g.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
본 발명의 마늘과 유지 혼합물로부터 아조엔을 생성하는 최적 조건을 제공하고, 본 발명의 방법에 의해 종래의 방법보다 2배 이상 높은 수율로 아조엔을 제조할 수 있으며, Z/E 비율이 높아 생리활성면에서 유리한 아조엔 함유 마늘 오일, 아조엔 강화 건강기능식품을 제조할 수 있으며, 대량생산에 적합한 공정 프로토콜을 갖는다.
It provides the optimum conditions for producing azoene from the garlic and oil and fat mixture of the present invention, by the method of the present invention can be produced in a yield more than twice the conventional method, the Z / E ratio is high physiological Azoene-containing garlic oil, azoene-enriched dietary supplement, which is advantageous in terms of activity, can be prepared and has a suitable process protocol for mass production.
도 1은 본 발명자들에 의해 정립된 아조엔 화합물의 분석 방법의 결과를 보여주는 고속액체크로마토그래피(HPLC)의 크로마토그램이다. (A) 아조엔 이성질체 표준물질, (B) 유지방과 마늘 착즙액을 이용한 반응결과물, 및 (C) 블랭크.
도 2는 본 발명의 하나의 실시예에 따른 아조엔 강화 건강기능식품의 제조공정도로서, 1단계로서 마늘로부터 마늘 착즙 잔사, 마늘 착즙액 및 마늘 추출물을 제조하는 것이고 2단계는 마늘과 유지방을 혼합하여 아조엔의 생성를 극대화하는 단계이며 3단계는 아조엔을 추출, 정제 안정화시키는 단계이다.
도 3는 마늘 착즙액으로부터 아조엔 제조의 최적화를 나타내는 반응표면도이다. (A)는 반응온도(X1)와 유지용량(X3)의 반응표면도, (B)는 반응시간(X2)와 반응온도(X1)의 반응표면도, (C)는 유지용량(X3)과 반응시간(X2)의 반응표면도이다.1 is a chromatogram of high performance liquid chromatography (HPLC) showing the results of the analytical method of the azoene compound established by the inventors. (A) Azoene isomer standard, (B) reaction product using milk fat and garlic juice, and (C) blank.
Figure 2 is a manufacturing process diagram of azoene fortified health functional food according to an embodiment of the present invention, the first step to prepare a garlic juice residue, garlic juice and garlic extract from garlic and the second step by mixing garlic and milk fat Maximize the production of azoene and the third step is to extract and purify the azoene.
Figure 3 is a reaction surface diagram showing the optimization of azoene production from garlic juice. (A) is the reaction surface diagram of reaction temperature (X1) and holding capacity (X3), (B) is the reaction surface diagram of reaction time (X2) and reaction temperature (X1), (C) is the holding surface (X3) and It is a reaction surface diagram of reaction time (X2).
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당 업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실험예Experimental Example 1: 마늘-유지 혼합물에 존재하는 1: present in garlic-maintenance mixture 아조엔Azoen (( ajoeneajoene ) 화합물의 분석방법 Analysis method of compound
실험에 사용한 시료는 2010년 난지형 깐마늘을 구입하여 사용하였다. 구입한 마늘은 파쇄기(OSCAR, Kimhae Korea)로 분쇄하여 마늘 착즙 잔사와 착즙액으로 구분한 후, 마늘 착즙액만을 진공필름 포장지를 이용하여 포장한 후, -80℃에서 보관하면서 시료로 사용하였다.The sample used for the experiment was purchased from 2010 Nanji type garlic. The purchased garlic was crushed with a crusher (OSCAR, Kimhae Korea) and divided into garlic juice residue and juice, and then only the garlic juice was packaged using a vacuum film wrapping paper and used as a sample while storing at -80 ℃.
마늘 착즙액 5 g에 유지방 함량이 80% 이상인 버터를 마늘 착즙액 중량의 1 내지 5배의 비율로 취한 후, 볼텍싱을 1분 동안 수행한 다음, 40℃에서 20분 동안 초음파 발생기를 이용하여 음파파쇄(sonication)를 실시하였다. 아조엔 생성을 위하여 일정 온도로 고정한 건조 오븐에서 유지와 마늘 착즙액을 일정시간 반응시킨 후 4000 rpm에서 5분 동안 원심분리시킨 다음, 상층액을 취하여 각 유지별로 에틸아세테이트를 이용하여 2-4배 희석한 다음 아조엔 함량을 측정하였다. 아조엔 함량은 자외선 검출기(JASCO, 2075 plus)와 실리카겔 컬럼(Agilent, 4.6× 250 mm, 5 μm)이 장착된 HPLC(JSACO, 펌프;2089 plus, 주입기;2057 plus, 칼럼오븐; 2067 plus)를 사용하였다. HPLC분리를 위한 이동상 조성은 헥산과 2-프로판올의 85:15 비율이며, 유속은 0.8 ㎖/min, 주입 용량은 5 ㎕로 하였으며, UV 파장은 240 ㎚로 설정하여 분석하였다(도 1).
In 5 g of garlic juice, butter with a milk fat content of 80% or more is taken at a ratio of 1 to 5 times the weight of garlic juice, followed by vortexing for 1 minute, and then using an ultrasonic generator at 40 ° C. for 20 minutes. Sonication was performed. In the drying oven fixed at a constant temperature for the production of azoene, the oil and garlic juice were reacted for a certain time, centrifuged at 4000 rpm for 5 minutes, and then the supernatant was taken and used for each oil 2-4 times using ethyl acetate. After dilution, the azoene content was measured. The azoene content was determined using HPLC (JSACO, pump; 2089 plus, injector; 2057 plus, column oven; 2067 plus) equipped with an ultraviolet detector (JASCO, 2075 plus) and a silica gel column (Agilent, 4.6 × 250 mm, 5 μm). Used. The mobile phase composition for HPLC separation was 85:15 ratio of hexane and 2-propanol, the flow rate was 0.8 ml / min, the injection volume was 5 μl, and the UV wavelength was set to 240 nm for analysis (FIG. 1).
제조예Manufacturing example 1: 식용유지 종류에 따른 1: according to the type of edible oils and fats 아조엔Azoen 함유 마늘 오일의 제조 Preparation of Containing Garlic Oil
10 ㎏의 깐마늘을 파쇄기(OSCAR, Kimhae Korea)로 분쇄하여 분쇄물을 얻고, 이를 압착하여 여과포로 걸러서 마늘 착즙액(1차)와 착즙 잔사를 각각 6 kg 및 4 kg을 얻었다. 10 kg of garlic was crushed with a crusher (OSCAR, Kimhae Korea) to obtain a pulverized product, which was compressed and filtered through a filter cloth to obtain 6 kg and 4 kg of garlic juice (primary) and juice residue, respectively.
상기 마늘 착즙액 5 g에 유지방(지방 함량 80 중량% 이상), 식용유지(7종) 및 중성중쇄지방산(MCT유)을 각각 15 g을 첨가하여 잘 혼합한 후 40℃의 초음파 발생 수욕조에서 20분 동안 초음파처리을 실시하였다.To 5 g of the garlic juice, 15 g of milk fat (fat content of 80% by weight or more), edible oils and fats (7 kinds), and neutral medium-chain fatty acid (MCT oil) were added and mixed well, respectively, in a 40 ° C. ultrasonic bath. Sonication was performed for 20 minutes.
식용유지에 따른 아조엔 함량을 비교하기 위한 반응 조건으로는 반응온도 65℃, 반응시간 2 시간 및 오일 함량은 착즙액 중량의 3배로 하여 각각 아조엔 함유 마늘 오일을 제조하였다.
Reaction conditions for comparing the azoene content according to the edible oil and fat as a reaction temperature 65 ℃, the
실험예Experimental Example 2: 식용유지 종류에 따른 2: according to the type of edible oils and fats 아조엔Azoen 함량 비교 Content comparison
상기 제조예 1에서 제조한 식용유지를 달리하여 제조한 아조엔 함유 마늘 오일의 아조엔 함량(Z-아조엔과 E-아조엔의 총합)을 계산하여 표 1에 나타내었다. The azoene content (total of Z-azoene and E-azoene) of the azoene-containing garlic oils prepared by different edible oils prepared in Preparation Example 1 was calculated and shown in Table 1 below.
* : 던컨(duncan's) 다중비교테스트 결과 유지방a과 식용유지b 간 유의성(P<0.05) *: Significance between milk fat a and edible oil b according to Duncan's multiple comparison test (P <0.05)
마늘 착즙액 100 중량부에 300 중량부의 유지를 혼합하여 반응시켰을 때, 마늘 착즙액 단위 g 당 아조엔 함량은 553 내지 1301 ㎍이었으며, 유지 단위 g당 아조엔 함량은 185 내지 434 ㎍이었다. 특히 유지방을 사용한 경우 다른 식물성 유지 또는 MCT유에 비하여 약 2 배 정도 높은 아조엔이 생성되었음을 확인할 수 있었다.
When the mixture was reacted by mixing 300 parts by weight of fat or oil with 100 parts of garlic juice, the azoene content per gram of garlic juice was 553 to 1301 µg, and the azoene content per gram of oil was 185 to 434 µg. In particular, when milk fat was used, it was confirmed that about 2 times higher azoene was produced than other vegetable oil or MCT oil.
실험예Experimental Example 3: 식용유지 종류에 따른 3: according to the type of edible oils and fats 아조엔의Azoen Z/E 비율 Z / E ratio
상기 제조예 1에서 제조한 식용유지를 달리하여 제조한 아조엔 함유 Z-아조엔과 E-아조엔의 비율, 즉 Z/E 비율을 계산하여 표 2에 나타내었다. The ratio of azoene-containing Z-azoene and E-azoene prepared by changing the edible oil prepared in Preparation Example 1, that is, Z / E ratio is calculated and shown in Table 2.
유지방은 올리브유에 비해서는 Z/E 비율이 낮았으나, 나머지 포도씨유, 콩기름, 들기름, 참기름, 옥수수유 및 MCT유에 비해서는 Z/E 비율이 높게 나타났다.
Buttermilk had a lower Z / E ratio than olive oil, but a higher Z / E ratio than the rest of grape seed oil, soybean oil, perilla oil, sesame oil, corn oil and MCT oil.
제조예Manufacturing example 2: 반응온도에 따른 유지방을 이용한 2: using milk fat according to reaction temperature 아조엔Azoen 함유 마늘 오일의 제조 Preparation of Containing Garlic Oil
상기 제조예 1의 마늘 착즙액과 유지방을 이용하여 제조예 1과 동일 방법으로 아조엔 함유 유지를 제조하되, 반응온도의 경우만 각각 40, 60, 80, 100 ℃로 변경하여 아조엔 함유 마늘 오일을 제조하였다.
Azoene-containing fat or oil was prepared in the same manner as in Preparation Example 1 using the garlic juice and milk fat of Preparation Example 1, but the reaction temperature was changed to 40, 60, 80, and 100 ° C., respectively, to azoene-containing garlic oil. Was prepared.
실험예Experimental Example 3: 식용유지 종류에 따른 3: according to the type of edible oils and fats 아조엔의Azoen Z/E 비율 Z / E ratio
상기 제조예 2에서 제조한 반응온도를 달리하여 제조한 아조엔 함유 Z-아조엔과 E-아조엔의 비율, 즉 Z/E 비율을 계산하여 표 3에 나타내었다. The ratio of azoene-containing Z-azoene and E-azoene prepared by varying the reaction temperature prepared in Preparation Example 2, that is, Z / E ratio is calculated and shown in Table 3.
반응온도 60 내지 70 ℃ 범위에서 다른 온도에 비해 Z/E 비율이 8 이상으로 현저히 높게 나타남을 확인하였다.
It was confirmed that the Z / E ratio was markedly higher than 8 in the reaction temperature range of 60 to 70 ° C. compared with other temperatures.
실험예Experimental Example 4: 반응표면 분석을 통한 마늘에서 4: from garlic by response surface analysis 아조엔Azoen 생성 조건 최적화 Generation condition optimization
실험예 2에서 아조엔이 가장 많이 생성되는 동물성 지방인 유지방(지방 함량 80 중량% 이상)을 이용하여 아조엔 최대 생성 조건을 탐색하였다. 이를 위하여 반응표면분석법(Response Surface Methodology)을 사용하였으며 실험 계획은 중심합성계획(Central Composite of Design: CCD)을 이용하였다. 독립변수 3요인으로는 반응온도(X1), 반응시간(X2), 오일 함유량(X3)으로서 5 수준(-2, -1, 0, 1, 2)으로 부호화 하였으며(표 1), 독립변수에 영향을 받는 종속변수는 마늘-유지방 혼합물에서의 아조엔 생성량(Y)으로 설정하여 각각 설정된 17개의 조건으로 실험을 실행하였다.In Experimental Example 2, the maximum production conditions of azoene were explored using milk fat (fat content of 80% by weight or more), which is the animal fat in which azoene is most produced. For this purpose, Response Surface Methodology was used, and the experimental design was based on the Central Composite of Design (CCD). The three independent variables included reaction temperature (X1), reaction time (X2) and oil content (X3) at five levels (-2, -1, 0, 1, 2) (Table 1). The dependent variable was set to the amount of azoene production (Y) in the garlic-fatty fat mixture, and the experiment was performed under 17 conditions.
중심합성계획법에 의한 마늘로부터 유지방을 이용하여 아조엔을 생성하는 조건을 표 4에 나타내었다.Table 4 shows the conditions for producing azoene from garlic by the central synthetic scheme.
(times by weight)Oil volume
(times by weight)
자료의 통계처리는 SAS package ver. 8.2(SAS Institute Inc., Cary, NC, 미국)를 이용하였다. 독립변수와 종속변수와의 관계를 다항회귀식으로 표현하였고, 다항회귀식을 바탕으로 maple 7(Waterloo maple Inc. 캐나다)을 이용하여 3차원 반응표면 그래프를 나타내었다(도 3).Statistical processing of data was performed by SAS package ver. 8.2 (SAS Institute Inc., Cary, NC, USA) was used. The relationship between the independent variable and the dependent variable was expressed by polynomial regression, and a three-dimensional response surface graph was shown using maple 7 (Waterloo maple Inc. Canada) based on the polynomial regression (FIG. 3).
마늘-유지방 혼합물에서의 아조엔 생성의 주요한 독립 변수인 반응온도(20-100℃), 반응시간(1-8 hr) 및 오일함유량(1-5배)에 따른 실험결과는 표 5에 나타내었으며, 아조엔 함량은 85.5-848.2 ㎍/g(마늘 착즙액)의 값을 나타내었으며, 반응표면 회귀분석을 분석한 결과(표 6), R²는 0.9189로써 1에 가깝고 유의성은 0.0045로 1% 이내의 유의수준에서 유의성이 인정되었다. The experimental results according to reaction temperature (20-100 ℃), reaction time (1-8 hr) and oil content (1-5 times), which are the main independent variables of azoene production in garlic-fat mixtures, are shown in Table 5. , Azoene content was 85.5-848.2 ㎍ / g (garlic juice) value, analysis of response surface regression analysis (Table 6), R² is 0.9189, close to 1, the significance is 0.0045 within 1% Significance was recognized at the significance level.
중심합성계획에 의한 아조엔 생성 조건별 시험 값을 표 5에 나타내었고, 반응표면분석에 의한 아조엔 화합물 생성을 위한 다항식을 표 6에 나타내었다.Table 5 shows the test values for azoene production conditions according to the central synthesis plan, and the polynomials for the generation of azoene compounds by reaction surface analysis are shown in Table 6.
(㎍/g, 마늘 착즙액)Azoene content
(Μg / g, garlic juice)
(℃)Reaction temperature
(℃)
(hr)Reaction time
(hr)
(times by weight)Oil content
(times by weight)
함량
(mg/g, 마늘착즙액)Azoen
content
(mg / g, garlic juice)
중심합성계획에 의해 설계된 실험조건으로 아조엔 함량변화를 3차원 반응표면으로 분석한 결과 도 3과 같은 최대점 형태를 나타내었다.As a result of analyzing the change of azoene content by the three-dimensional reaction surface under the experimental conditions designed by the central synthesis plan, the maximum point shape is shown in FIG.
이상의 결과에서 마늘-유지방 혼합물을 이용하여 아조엔 생성에 적합한 최적조건은 반응온도 61.05℃, 반응시간 2.56 hr 및 오일함유량은 3.63으로 나타났다(표 7). 즉 마늘-유지방 혼합물을 이용하여 최적 생성조건으로 반응시킴으로써 아조엔을 기존의 특허 방법보다 2배 이상 증가시키는 농도로 생성되었다. In the above results, the optimum conditions for producing azoene using garlic-fatty fat mixture were 61.05 ° C, reaction time 2.56 hr, and oil content 3.63 (Table 7). In other words, by using the garlic-fat mixture to react at the optimum production conditions, azoene was produced at a concentration that is more than two times higher than the existing patent method.
(ug/g, 마늘 착즙액)Azoene content
(ug / g, garlic juice)
또한 마늘-유지방 혼합물의 아조엔 함량 회귀모델에 대한 분산분석(유의성 분석) 결과를 표 8에 나타내었다. In addition, the results of analysis of variance (significance analysis) of the azoene content regression model of garlic-fat mixtures are shown in Table 8.
* 10% 수준에서의 유의성, ** 1% 수준에서 유의성 * Significance at 10%, ** significance at 1%
표 8에서와 같이 아조엔 생성량에 대한 반응조건의 영향은 반응시간 보다는 반응 온도와 오일 함유량이 더 많은 영향을 미치는 것을 알 수 있었다.
As shown in Table 8, the effect of reaction conditions on the amount of azoene produced was found to affect the reaction temperature and oil content more than the reaction time.
실험예Experimental Example 5: 유지방과 마늘 5: butterfat and garlic 착즙액Juice 혼합비율에 따른 According to the mixing ratio 아조엔Azoen 생성량 비교 Generation amount comparison
시중에서 구입한 밀크 크림(유지방함량 32.5%)을 원심분리방법에 의거 지방 함량이 94.5%인 유지방제품을 제조할 수 있었다. 이와 같이 제조한 유지방과 마늘 착즙액의 혼합비를 달리하여 아조엔 생성량을 비교하였다. Milk cream (32.5% milk fat content) purchased commercially was able to prepare a milk fat product having a fat content of 94.5% by centrifugation. Azoene production was compared by varying the mixing ratio of the milk fat and garlic juice prepared in this way.
마늘 착즙액을 상기에서 제조한 유지방과 마늘 착즙액을 합한 총 중량의 10 내지 70 중량%가 되도록 각각 합한 후 볼텍스을 이용하여 혼합시켜 준 다음 40℃에서 20분 동안 소니케이션(sonication)처리를 하였다, 이를 65℃로 고정한 water bath에서 3시간 반응시켜 아조엔을 생성시켰다.Garlic juice was added to 10 to 70% by weight of the total weight of the milk fat and garlic juice prepared above, and then mixed by vortex and then subjected to sonication (sonication) for 20 minutes at 40 ℃, This was reacted for 3 hours in a water bath fixed at 65 ℃ to produce azoene.
표 9에는 유지방과 마늘 착즙액의 혼합비율에 따른 생성된 아조엔의 함량을 분석한 결과를 나타내었다.Table 9 shows the results of analyzing the content of azoene produced according to the mixing ratio of milk fat and garlic juice.
마늘 착즙액 10 중량%를 혼합하여 제조했을 때의 아조엔 함량은 53.2 ㎍/유지방g 이었고, 마늘 착즙액의 함량을 60 중량%까지 증가시킬수록 아조엔 함량은 증가하는 것으로 나타났다. 그러나 마늘 착즙액의 함량을 70 중량%로 높일 경우에는 아조엔 함량이 오히려 감소하였다.The azoene content was prepared by mixing 10% by weight of the garlic juice was 53.2 ㎍ / fat g, the azoene content was increased as the content of the garlic juice to 60% by weight. However, when the content of garlic juice was increased to 70% by weight, the azoene content was rather decreased.
또한, 상기 제조된 아조엔 함유 마늘 오일의 지방 함량을 측정하기 위하여, 검사시료 1-1.5g을 정밀히 취하여 50 mL의 비이커에 취하고 에테르로 분액깔대기에 씻어 넣은 다음, 무수황산나트륨을 가하여 탈수한 후, 250 mL의 삼각플라스크에 여과하고 에테르를 날려 보낸 후, 105℃에서 항량이 될 때까지 건조하여 지방의 양을 산출하였다. 상기 아조엔 함유 마늘 오일의 지방 함량은 94.33 중량% 이었다.
In addition, in order to measure the fat content of the prepared azoene-containing garlic oil, 1-1.5 g of the test sample was precisely taken, taken in a beaker of 50 mL, washed in a separatory funnel with ether, and dehydrated by adding anhydrous sodium sulfate. Filtration was carried out in a 250 mL Erlenmeyer flask, ether was blown off, and dried at 105 ° C. until yielded to yield an amount of fat. The fat content of the azoene-containing garlic oil was 94.33% by weight.
제조예Manufacturing example 3: 3: 아조엔Azoen 강화 유지 함유 소프트-쉘 캡슐 제조 Soft-shell capsule manufacture with fortified oils and fats
실험예 3의 마늘 착즙액과 유지방을 5:5 중량비로 혼합하여 반응시켜 제조한 아조엔 함유 마늘 오일(2000 ㎍/g유지방)을 원심분리하여 상등액을 취하고, 캅셀 하나당 상등액 500 mg을 포함하도록 젤라틴으로 소프트-쉘 캡슐을 제조하였다.
Centrifugation of azoene-containing garlic oil (2000 ㎍ / g milk fat) prepared by mixing garlic juice and milk fat of Experimental Example 3 in a 5: 5 weight ratio to take a supernatant and gelatin to contain 500 mg of supernatant per capsule Soft-shell capsules were prepared.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (17)
상기 알리신 함유 마늘 재료를 유지방과 혼합하는 단계; 및
상기 알리신 함유 마늘 재료와 유지방의 혼합물을 가열하여 반응시키는 단계;를 포함하는 유지방을 이용한 아조엔 함유 마늘 오일의 제조방법.Preparing at least one allicin containing garlic material selected from garlic grind, garlic juice, garlic dry powder and garlic extract;
Mixing the allicin-containing garlic material with milk fat; And
A method of producing azoene-containing garlic oil using a milk fat comprising a; reacting by heating the mixture of allicin-containing garlic material and milk fat.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120044932A KR101342110B1 (en) | 2011-05-02 | 2012-04-27 | Process for Preparing Edible Oil Containing Ajoene from Garlic |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110041443 | 2011-05-02 | ||
KR20110041443 | 2011-05-02 | ||
KR1020120044932A KR101342110B1 (en) | 2011-05-02 | 2012-04-27 | Process for Preparing Edible Oil Containing Ajoene from Garlic |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120124038A KR20120124038A (en) | 2012-11-12 |
KR101342110B1 true KR101342110B1 (en) | 2013-12-18 |
Family
ID=47509544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120044932A KR101342110B1 (en) | 2011-05-02 | 2012-04-27 | Process for Preparing Edible Oil Containing Ajoene from Garlic |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101342110B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9934750B2 (en) | 2014-02-24 | 2018-04-03 | Samsung Display Co., Ltd. | Data driver, display apparatus having the same and method of driving display panel using the same |
KR102424430B1 (en) | 2021-11-18 | 2022-07-26 | 주식회사 다림바이오텍 | A preparation method of garlic powder |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101472277B1 (en) * | 2013-08-12 | 2014-12-15 | 우희석 | Garlic ice cream |
KR102104923B1 (en) * | 2018-08-06 | 2020-04-27 | 세명대학교 산학협력단 | Pesticide-removed crude drug extract through ultrasonic thermal fusion treatment and process for thereof |
-
2012
- 2012-04-27 KR KR1020120044932A patent/KR101342110B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9934750B2 (en) | 2014-02-24 | 2018-04-03 | Samsung Display Co., Ltd. | Data driver, display apparatus having the same and method of driving display panel using the same |
KR102424430B1 (en) | 2021-11-18 | 2022-07-26 | 주식회사 다림바이오텍 | A preparation method of garlic powder |
Also Published As
Publication number | Publication date |
---|---|
KR20120124038A (en) | 2012-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5885153B2 (en) | Manufacturing method of processed ginger | |
CN104254524B (en) | The manufacture method of the compositions containing fucoxanthine | |
JP6265388B2 (en) | New extracts of artichoke, coffea and olive for treating metabolic syndrome | |
KR101342110B1 (en) | Process for Preparing Edible Oil Containing Ajoene from Garlic | |
KR101374079B1 (en) | Process for Preparing Milk Butter Containing Ajoene from Garlic | |
JP2013202005A (en) | Curcumin-containing oil and fat, and method for producing the same | |
JP6307760B2 (en) | Method for producing celery family plant extract | |
Cravotto et al. | Green extraction techniques | |
JP2020128439A (en) | Anti-aging agent | |
Adu et al. | Effect of processing on the quality, composition and antioxidant properties of Terminalia catappa (indian almond) seed oil | |
JP2009057481A (en) | Antioxidant composition | |
CN101695324A (en) | Method for manufacturing fat lowering tea capable of adjusting blood fat | |
JP6042800B2 (en) | Tomatoside A extraction method | |
JPH04139132A (en) | Anti-active oxygen action composition, anti-active oxygen agent, food, cosmetic and medicine containing the same as active ingredient | |
KR101100120B1 (en) | Edible Oil Comprising Ginseng Oil extracted from Ginseng or its Residue Extract and Preparation Method The Same | |
JP2012121840A (en) | Blood triglyceride level rise inhibitor | |
KR101252578B1 (en) | Manufacturing method of pine-nut oil using centrifugation | |
KR101426404B1 (en) | Extracts from Brown Rice Bran Having Nutritional Ingredients and Methods for Preparing the Same | |
EP2464713B1 (en) | Process for the preparation of an integral olive juice, composition so obtained, and its use in cosmetic and in dietetic fields | |
KR101735666B1 (en) | Edible-oil containing cordyceps militaris and manufacturing process thereof | |
KR101947889B1 (en) | Manufacturing method of embryo bud of rice containing sparassis crispa extract and embryo bud of rice containing sparassis crispa extract prossed product using the same | |
CN110236058A (en) | A kind of production technology of soybean germ flavor solids beverage | |
KR101671490B1 (en) | Mineral increased nuts and method for preparing the same | |
KR102713809B1 (en) | Manufacturing method for evening primrose oil and evening primrose oil by the same | |
JP6806729B2 (en) | An edible composition containing black soybean seed coat extract and long pepper extract as essential components for enhancing serum nitric oxide production, promoting improvement of antioxidant function in liver, and promoting function of lowering triglyceride content in serum. Vascular endothelial function improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20161101 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20171103 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200205 Year of fee payment: 7 |